MD Anderson and Cellectis announce pre-clinical and clinical alliance in cancer immunotherapy

Cellectis, the gene editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news